Coherus BioSciences, Inc.
http://www.coherus.com/
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Coherus BioSciences, Inc.
Coherus All But Checks Out Of Biosimilars With Meitheal Adalimumab Deal
Meitheal Pharmaceuticals can begin preparations for a seminal moment, the firm’s first marketed US biosimilar, as it snapped up rights to Humira rival Yusimry from Coherus BioSciences.
Biosimilars: US FDA Heralds The End Of Switching Studies For Interchangeability
New guidance suggests that switching studies will no longer be expected as standard to support determinations of biosimilar interchangeability; instead, analytical and clinical data may suffice.
Who’s Hired? Lupin Appoints CEO To New API CDMO Subsidiary
Lupin has selected a CEO to lead its fresh API CDMO business venture, while the UK’s off-patent group BGMA has appointed a new vice-chair. Meanwhile, ChemWerth has welcomed a familiar face as its new president and Coherus has elected a new board member with a focus on immuno-oncology.
Coherus Positive And Up For The Fight Amid Amneal Pegfilgrastim Deals
Coherus BioSciences feels its bearing and clout in the US pegfilgrastim market will stand it in good stead as other players scrabble to compete on the more lucrative formulations of Amgen’s Neulasta.
Company Information
- Industry
-
Pharmaceuticals
- Generic Drugs
-
Biotechnology
-
Large Molecule
- Antibodies
-
Large Molecule
- Other Names / Subsidiaries
-
- InteKrin Therapeutics, Inc.
- Coherus Intermediate Corp
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice